Findings published in Nature showing that dual blockage of PD-L1 and CD47 can boost the therapeutic effects of oxaliplatin chemotherapy as well as the FOLFOX regimen – in a CT-26 mice tumor model, anyway – served to highlight CD47, a target that has spurred added efforts of late.
Medshine Discovery Inc. has divulged nuclear receptor ROR-γ (RORC) agonists or RORC inverse agonists reported to be useful for the treatment of cancer.
Lymphatic malformation (LM), a vascular anomaly originating from lymphatic endothelial cells, can progress to malignant lymphangiosarcoma (LAS) in a fraction of patients. Scientists from the University of Cincinnati College of Medicine recently conducted a study to unveil the mechanisms underlying LM malignant transformation to LAS and found that inhibiting autophagy can prevent this malignant transformation.
Radiotherapy is commonly used to treat solid tumors; promoting DNA damage in tumoral cells is the main mechanism for its cytotoxic effect, and its potential to induce innate and adaptive immune responses is being explored.
In a striking demonstration of how the success of mRNA vaccines against COVID-19 has opened up the potential of the technology in cancer, mice that cleared a tumor after a single administration of an mRNA vaccine, also cleared a second tumor without receiving further immunization. This display of potent immunogenicity formed part of a head-to-head study of three different mRNA technology platforms in human papillomavirus (HPV)-16 associated tumors.
Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in 2019, Immorna develops therapeutics and vaccines based on its RNA platforms, including conventional, self-replicating and circular RNA.
RSS
